Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded by Truist Financial to “Strong-Buy” Rating

Truist Financial upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) to a strong-buy rating in a research note published on Wednesday morning,Zacks.com reports.

Several other analysts have also weighed in on RARE. Jefferies Financial Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. HC Wainwright reduced their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. The Goldman Sachs Group lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $61.00 to $25.00 in a research report on Tuesday. Bank of America dropped their price target on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Finally, Robert W. Baird cut their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.47.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $19.85 on Wednesday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -3.40 and a beta of 0.16. The firm’s 50-day simple moving average is $22.51 and its 200-day simple moving average is $28.23. Ultragenyx Pharmaceutical has a twelve month low of $18.29 and a twelve month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same period in the prior year, the business earned ($1.39) earnings per share. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the sale, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Richard Pinion sold 10,029 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $228,661.20. Following the transaction, the insider owned 110,026 shares in the company, valued at approximately $2,508,592.80. The trade was a 8.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 104,958 shares of company stock valued at $2,394,858 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Covestor Ltd lifted its holdings in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares during the period. Huntington National Bank grew its holdings in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the period. Xponance Inc. grew its holdings in Ultragenyx Pharmaceutical by 3.1% during the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 406 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 2.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 434 shares during the last quarter. Finally, Amalgamated Bank raised its position in shares of Ultragenyx Pharmaceutical by 6.9% during the 3rd quarter. Amalgamated Bank now owns 7,226 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 469 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Conflicting short‑interest data released today shows reports of a “large increase” but the published figures read as zero/NaN, indicating the data is likely erroneous or incomplete — do not rely on these short‑interest numbers for trading signals.
• Negative Sentiment: Goldman Sachs downgraded RARE from buy to neutral and slashed the price target to $25 (from $61), citing concerns about setrusumab data — this analyst action raises downward pressure and may prompt further investor re‑rating. Goldman Sachs Downgrade
• Negative Sentiment: Multiple law firms (Rosen, Bragar Eagel & Squire, Robbins LLP, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Pomerantz, Faruqi & Faruqi, etc.) issued notices about a securities‑fraud class action covering purchases from Aug 3, 2023–Dec 26, 2025 and an April 6, 2026 lead‑plaintiff deadline — increased litigation risk creates an overhang that can weigh on valuation and investor sentiment. Representative notices: Rosen (PR Newswire) Rosen Law Firm Notice, Bragar (GlobeNewsWire) Bragar Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.